- Trial phase
- Pivotal (registrational)
- Time to market
- If the 1H 2027 pivotal data and FDA feedback are positive, a BLA submission could follow in 2027-2028, with potential approval in 2028-2029. This timeline depends on the regulatory pathway the FDA outlines.
- Why 8/10
- The next hard, dated catalyst is the topline 6-month interim analysis from the REVEAL pivotal trial and FDA feedback on the BLA submission pathway, expected in the first half of 2027 (roughly 2-7 months from today). TSHA-102 is the company's sole clinical-stage asset, making this a make-or-break binary for a single-asset biotech, warranting an impact score of 8.
The next major binary catalyst is the topline 6-month interim analysis from the REVEAL pivotal trial and FDA feedback on the BLA submission pathway, both expected in the first half of 2027. Positive data and regulatory alignment could open a clear path to approval and drive significant upside; negative data or FDA pushback would be a severe setback for this single-asset company.
Price Chart
Executive Summary
TSHA-102 is Taysha Gene Therapies' lead and only clinical-stage asset: a one-time intrathecal AAV9 gene therapy for Rett syndrome, a rare genetic neurological disorder. The drug has shown broad, durable functional improvements with a favorable safety profile in Phase 1/2 REVEAL Part A data, and has received FDA Breakthrough Therapy, RMAT, Fast Track, Orphan Drug, and Rare Pediatric Disease designations. Dosing in the 17-patient REVEAL pivotal trial completed in mid-2026. The next major catalyst is the topline 6-month interim analysis and FDA feedback on the BLA submission pathway, expected in the first half of 2027. Taysha is a single-asset biotech with roughly $455M in cash (runway into H2 2028) and a strongly bullish analyst consensus (mean target $13 vs ~$4.11 current). Competition from Neurogene's NGN-401 is a key risk.
How It Works
TSHA-102 is a one-time gene therapy for Rett syndrome, a rare genetic neurological disorder caused by mutations in the MECP2 gene. It uses a harmless AAV9 virus shell to deliver a working copy of the MECP2 gene directly into the central nervous system via a lumbar spinal injection. The therapy includes a built-in 'miRARE' regulatory element designed to prevent the therapy from producing too much MeCP2 protein, which could be toxic. The goal is to address the root genetic cause of Rett syndrome with a single treatment.
Trial Status
Dosing completed in the REVEAL pivotal trial (N=17 patients, ages 6+) and the ASPIRE trial (N=4, ages 2-5). Longer-term data from REVEAL Part A (Phase 1/2) showed broad, multi-domain functional impact that deepened over time through 12+ months post-treatment. The drug was generally well-tolerated with no treatment-related serious adverse events or dose-limiting toxicities. Topline data from the 6-month interim analysis of the pivotal trial is expected in 1H 2027.
The Two-Sided Case
Upcoming Catalysts
- Topline 6-month interim analysis from the REVEAL pivotal trial (expected 1H 2027)
- FDA feedback on BLA submission pathway (expected 1H 2027)
- Potential BLA filing (timeline dependent on FDA feedback)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Taysha Gene Therapies, Inc. PRESS-RELEASE TSHA ·Originating report